The global immunoncology therapy market is expected to grow at a CAGR of 12.2% during the forecast period, from 2021 to 2030. The growth of this market is driven by the increasing incidence of cancer and rising demand for immunotherapy drugs.
Monoclonal antibodies are one of the major types in this market and are expected to account for a significant share in terms of revenue generation during the forecast period. This type is used as an immune checkpoint inhibitor, which helps in preventing tumor cells from escaping from immune system surveillance and thus prevents tumor recurrence or metastasis. Immune system modulators are also another type that has been gaining traction due to their ability to stimulate or suppress immune responses depending on their mode of action. Cancer vaccines are also gaining popularity due to their ability to stimulate an individual’s own immune system against cancer cells without any adverse effects on healthy cells or tissues, thereby reducing side effects associated with other treatments such as chemotherapy and radiation therapy.
-The market for immuno-oncology therapies is expected to grow from $4.2 billion in 2015 to $14.5 billion by 2020, at a compound annual growth rate of 18%.
-The number of new cancer cases diagnosed each year is expected to increase from 14 million in 2012 to 22 million by 2030, and the number of deaths due to cancer is expected to increase from 8.2 million in 2012 to 13.3 million by 2030.
-Cancer patients are living longer with better treatments and more effective drugs, which has led many people with cancer who were previously not considered candidates for treatment because they had too little time left or their condition was too advanced, now have a chance at life extension through immunotherapy treatments that can be used as an adjuvant therapy or as a first line treatment option.
Industry Growth Insights published a new data on “Immuno-oncology Therapy Market”. The research report is titled “Immuno-oncology Therapy Market research by Types (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Others), By Applications (Hospitals, Ambulatory Surgical Center, Others), By Players/Companies Amgen, AstraZeneca, Bristol-Myers Squibb, Eli-Lilly, Roche, GlaxoSmithKline, Janssen Biotech, Merck, Novartis, Pfizer, Sanofi, Spectrum Pharmaceuticals, Takeda ”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Immuno-oncology Therapy Market Research Report
By Type
Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Others
By Application
Hospitals, Ambulatory Surgical Center, Others
By Companies
Amgen, AstraZeneca, Bristol-Myers Squibb, Eli-Lilly, Roche, GlaxoSmithKline, Janssen Biotech, Merck, Novartis, Pfizer, Sanofi, Spectrum Pharmaceuticals, TakedaÂ
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Immuno-oncology Therapy Market Report Segments:
The global Immuno-oncology Therapy market is segmented on the basis of:
Types
Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Center, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- AstraZeneca
- Bristol-Myers Squibb
- Eli-Lilly
- Roche
- GlaxoSmithKline
- Janssen Biotech
- Merck
- Novartis
- Pfizer
- Sanofi
- Spectrum Pharmaceuticals
- TakedaÂ
Highlights of The Immuno-oncology Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- Immune Checkpoint Inhibitors
- Immune System Modulators
- Cancer Vaccines
- Others
- By Application:
- Hospitals
- Ambulatory Surgical Center
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Immuno-oncology Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Immuno-oncology therapy is a type of cancer treatment that uses the bodyu2019s own immune system to fight cancer. Immuno-oncology therapies use various types of drugs and vaccines to help the bodyu2019s natural defenses attack and destroy tumors.
Some of the major companies in the immuno-oncology therapy market are Amgen, AstraZeneca, Bristol-Myers Squibb, Eli-Lilly, Roche, GlaxoSmithKline, Janssen Biotech, Merck, Novartis, Pfizer, Sanofi, Spectrum Pharmaceuticals, Takeda‚Â .
The immuno-oncology therapy market is expected to register a CAGR of 12.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Immuno-oncology Therapy Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Immuno-oncology Therapy Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Immuno-oncology Therapy Market - Supply Chain
4.5. Global Immuno-oncology Therapy Market Forecast
4.5.1. Immuno-oncology Therapy Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Immuno-oncology Therapy Market Size (000 Units) and Y-o-Y Growth
4.5.3. Immuno-oncology Therapy Market Absolute $ Opportunity
5. Global Immuno-oncology Therapy Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Immuno-oncology Therapy Market Size and Volume Forecast by Type
5.3.1. Monoclonal Antibodies
5.3.2. Immune Checkpoint Inhibitors
5.3.3. Immune System Modulators
5.3.4. Cancer Vaccines
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Immuno-oncology Therapy Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Immuno-oncology Therapy Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Ambulatory Surgical Center
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Immuno-oncology Therapy Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Immuno-oncology Therapy Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Immuno-oncology Therapy Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Immuno-oncology Therapy Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Immuno-oncology Therapy Demand Share Forecast, 2019-2026
9. North America Immuno-oncology Therapy Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Immuno-oncology Therapy Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Immuno-oncology Therapy Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Ambulatory Surgical Center
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Immuno-oncology Therapy Market Size and Volume Forecast by Type
9.7.1. Monoclonal Antibodies
9.7.2. Immune Checkpoint Inhibitors
9.7.3. Immune System Modulators
9.7.4. Cancer Vaccines
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Immuno-oncology Therapy Demand Share Forecast, 2019-2026
10. Latin America Immuno-oncology Therapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Immuno-oncology Therapy Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Immuno-oncology Therapy Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Center
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Immuno-oncology Therapy Market Size and Volume Forecast by Type
10.7.1. Monoclonal Antibodies
10.7.2. Immune Checkpoint Inhibitors
10.7.3. Immune System Modulators
10.7.4. Cancer Vaccines
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Immuno-oncology Therapy Demand Share Forecast, 2019-2026
11. Europe Immuno-oncology Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Immuno-oncology Therapy Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Immuno-oncology Therapy Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Center
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Immuno-oncology Therapy Market Size and Volume Forecast by Type
11.7.1. Monoclonal Antibodies
11.7.2. Immune Checkpoint Inhibitors
11.7.3. Immune System Modulators
11.7.4. Cancer Vaccines
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Immuno-oncology Therapy Demand Share, 2019-2026
12. Asia Pacific Immuno-oncology Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Immuno-oncology Therapy Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Immuno-oncology Therapy Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Center
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Immuno-oncology Therapy Market Size and Volume Forecast by Type
12.7.1. Monoclonal Antibodies
12.7.2. Immune Checkpoint Inhibitors
12.7.3. Immune System Modulators
12.7.4. Cancer Vaccines
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Immuno-oncology Therapy Demand Share, 2019-2026
13. Middle East & Africa Immuno-oncology Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Immuno-oncology Therapy Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Immuno-oncology Therapy Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Center
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Immuno-oncology Therapy Market Size and Volume Forecast by Type
13.7.1. Monoclonal Antibodies
13.7.2. Immune Checkpoint Inhibitors
13.7.3. Immune System Modulators
13.7.4. Cancer Vaccines
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Immuno-oncology Therapy Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Immuno-oncology Therapy Market: Market Share Analysis
14.2. Immuno-oncology Therapy Distributors and Customers
14.3. Immuno-oncology Therapy Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Amgen
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AstraZeneca
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bristol-Myers Squibb
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Eli-Lilly
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Roche
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. GlaxoSmithKline
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Janssen Biotech
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Merck
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Novartis
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Pfizer
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Sanofi
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Spectrum Pharmaceuticals
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Takeda
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
